Diabetes mellitus and osteoporosis

Current Diabetes Reports

Volumn 13, Issue 3, 2013, Pages 411-418

  Sealand, Robert ^a,b   Razavi, Christie ^a,b   Adler, Robert A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bone mineral density; Diabetes mellitus; Dual energy X ray absorptiometry; Fracture; Obesity; Osteocalcin; Osteoporosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CARTILAGE CELL; CELL DIFFERENTIATION; DISEASE ASSOCIATION; FRAGILITY FRACTURE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PREVALENCE; PROTEIN BINDING; PROTEIN EXPRESSION; RISK ASSESSMENT; SEX DIFFERENCE; WNT SIGNALING PATHWAY; ANIMAL; COMPLICATION; FRACTURES, BONE; PATHOPHYSIOLOGY;

ANIMALS; BONE DENSITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 84877775427     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0376-x     Document Type: Article

References (77)

1. World Health Organization: Diabetes Fact Sheet. Available at www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed December 2012.
2. Osteoporosis - General Statistics. Available at www.iofbonehealth.org/ facts-statistics#category-14. Accessed December 2012
3. Bonds D, Larson J, Schwartz A, et al. Risk of fracture in women with type 2 diabetes: the women's health initiative observational study. J Clin Endocrin Metab. 2006;91:3404-10. (Pubitemid 44402111)
4. Strotmeyer E, Cauley J, Schwartz A, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005;165:1612-1617. (Pubitemid 41124155)
5. Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27:319-32. This study clearly demonstrates the increased bone density of type 2 diabetes mellitus.
6. Nielson CM, Marshall LM, Adams AL, et al. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J Bone Miner Res. 2011;26:496-502. This prospective study of about 6,000 older men found that obesity was not protective of the skeleton. Indeed fracture risk was higher in obese men.
7. Tanaka S, Kuroda T, Saito M, Shiraki M. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women. Osteoporos Int. 2013;24:69-76.
8. Viegas M, Costa C, Lopes A, et al. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications. 2011;25:216-21.
9. Compston JE, Watts NB, Chapurlat R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011;124:1043-50.
10. Prieto-Alhambra D, Premaor MO, Fina Aviles F, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27:294-300.
11. Premaor MO, Compston JE, Aviles FF, et al. The association between fracture site and obesity in men: a population-based cohort study. J Bone Miner Res epublished 31 January 2013.
12. de Liefde I, Van der Klift M, de Laet C, et al. Bone mineral density and fracture risk in type 2 diabetes mellitus: the Rotterdam Study. Osteoporosis Int. 2005;16:1713-20. (Pubitemid 41790880)
13. Lipscombe L, Jamal S, Booth G, et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care. 2007;30:835-41. (Pubitemid 46556575)
14. Bonds D, Larson J, Schwartz A, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrin Metab. 2006;9:3404-10. (Pubitemid 44402111)
15. Mendez J, Rojano-Mejia D, Pedraza J, et al. Bone mineral density in postmenopausal Mexican-Mestizo women with normal body mass index, overweight, or obesity. Menopause epublished December 30, 2012.
16. Kao W, Kammerer C, Schneider J, et al. Type 2 diabetes is associated with increased bone mineral density in Mexican-American women. Arch Med Res. 2003;34:399-406. In women, obesity does not protect bones from fracture. (Pubitemid 38368706)
17. Melton LJ, Riggs BL, Leibson C, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 2008;93:4804-9.
18. Burghardt A, Issever A, Schwartz A, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:5045-55. Using new techniques, the alterations of cortical bone found in type 2 diabetes mellitus may be one explanation for the increased fracture risk.
19. Patsch J, Burghardt A, Yap S, et al. Increased cortical porosity in type-2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 2012 10.1002 Epub ahead of print
20. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45-9.
21. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1737-44.
22. Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:3744-50.
23. Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L. High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone. 2012;50:276-88.
24. Booth SL, Centi AM, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013;9:43-55. This review of osteocalcin looks at the potential role of this bone protein in glucose metabolism.
25. Iglesias P, Arrieta F, Pinera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-Crosslaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol. 2011;75:184-8.
26. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195-214.
27. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380-6.
28. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1013-9. (Pubitemid 351398587)
29. Pittas AG, Nelson J, Mitri J, et al. Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. Diabetes Care. 2012;35:565-73.
30. Harris SS, Pittas AG, Palermo NJ. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab. 2012;14:789-94.
31. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8:178-84.
32. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231-7. This important review of diabetes and fracture risk includes explanation of how the FRAX risk calculator should be viewed in patients with diabetes.
33. Dunger DB, Acerini CL. IGF-I and diabetes in adolescence. Diabetes Metab. 1999;24:101-7. (Pubitemid 28239806)
34. Johnson SB, Silverstein J, Rosenbloom A, Carter R, Cunningham W. Assessing daily management in childhood diabetes. Health Psychol. 1986;5:545-64.
35. Weissberg-Benchell J, Glasgow AM, Tynan WD, et al. J. Adolescent diabetes management and mismanagement. Diabetes Care. 1995;18:77-8.
36. Albertson AM, Tobelmann RC, Marquart L. Estimated dietary calcium intake and food sources for adolescent females 1980-1992. J Adolesc Health. 1997;20:20-6. (Pubitemid 27027354)
37. Thrailkill KM. Diabetes care for adolescents. In: Reece EA, Coustan DR, Gabbe SG, editors. Diabetes in women. Philadelphia: Lippincott Williams & Willkins; 2004.
38. Brown IR, McBain AM, Chalmers J, et al. Sex differences in the relationship of calcium and magnesium excretion to glycaemic control in type 1 diabetes mellitus. Clin Chim Acta. 1999;283:119-28. (Pubitemid 29324958)
39. Holmes GKT. Screening for coeliac disease in type 1 diabetes. Arch Dis Child. 2002;87:495-9. (Pubitemid 35440700)
40. Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab. 1998;11:413-9. (Pubitemid 28317370)
41. Pascual J, Argente J, Lopez MB, et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int. 1998;62:31-5. (Pubitemid 28018672)
42. Valerio G, del Puente A, Esposito-del Puente A, et al. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58:266-72. (Pubitemid 35404237)
43. Saha MT, Sievanen H, Salo MK, et al. Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers. Osteoporos Int. 2009;20:1401-6.
44. Gunczler P, Lanes R, Paoli M, et al. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001;14:525-8. (Pubitemid 32479530)
45. Salvatoni A, Mancassola G, Biasoli R, et al. Bone mineral density in diabetic children and adolescents: a follow-up study. Bone. 2004;34:900-4. (Pubitemid 38581136)
46. Hadjidakis DJ, Raptis AE, Sfakianakis M, Mylonakis A, Raptis SA. Bone mineral density of both genders in type 1 diabetes according to bone composition. J Diabetes Complications. 2006;20:302-7. (Pubitemid 44308584)
47. Hamilton EJ, Rakic V, Davis WA, et al. A five-year prospective study of bone mineral density in men and women with diabetes: The Fremantle Diabetes Study. Acta Diabetol. 2012;49:153-8.
48. Liu EY, Wactawski-Wende J, Donahue RP, et al. Does Low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care. 2003;26:2365-9. (Pubitemid 36993327)
49. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22:1317-28. (Pubitemid 351339677)
50. Nicodemus KK, Folsom AR. Iowa Women's Health Study: type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192-7. (Pubitemid 33716397)
51. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007;18:427-44. (Pubitemid 46354916)
52. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004;3:379-89. (Pubitemid 40246708)
53. Lecka-Czernik B, Gubrij I, Moerman EA, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem. 1999;74:357-71. (Pubitemid 29344887)
54. Botolin S, McCabe LR. Inhibition of PPAR-Gamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol. 2006;209:967-76. (Pubitemid 44665719)
55. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk. J Intern Med. 2000;248:67-76. (Pubitemid 30470006)
56. Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011;226:477-83. This study provides insight into how diabetes affects osteoblasts.
57. Maor G, Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology. 1999;140:1841-51. (Pubitemid 29149257)
58. Nixon AJ, Lillich JT, Burton-Wurster N, et al. Differentiated cellular function in fetal chondrocytes cultured with insulin-like growth factor-I and transforming growth factor-beta. J Orthop Res. 1998;16:531-41. (Pubitemid 28512431)
59. Wan Y, Chong LW, Evans RM. PPAR-Gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496-503. (Pubitemid 350224244)
60. Williams JP, Blair HC, McDonald JM, et al. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun. 1997;235:646-51. (Pubitemid 27326536)
61. Fraser JH, Helfrich MH, Wallace HM, Ralston SH. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone. 1996;19:223-6. (Pubitemid 26302605)
62. Pater A, Sypniewska, Pilecki O. Biochemical markers of bone cell activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23:81-6.
63. Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 1997;138:3849-58. (Pubitemid 27351939)
64. Thomas DM, Udagawa N, Hards DK, et al. Insulin receptor expression in primary and cultured osteoclast-like cells. Bone. 1998;23:181-6. (Pubitemid 28434661)
65. Conover CA, Lee PD, Riggs BL, Powell DR. Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: regulation by insulin and glucocorticoid. Endocrinology. 1996;137:3295-301. (Pubitemid 26250178)
66. Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res. 2008;23:1884-91.
67. Pastor MMC, Lopez-Ibarra PJ, Escobar-Jimenez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int. 2000;11:455-9. (Pubitemid 30450130)
68. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear-kappa B. Diabetes. 2001;50:2792-808. (Pubitemid 33733131)
69. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation endproducts (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6:7-14.
70. Zhang Y, Papasian CJ, Deng HW. Alterations of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss. Osteoporos Int. 2011;22:1781-8.
71. Bronsky J, Prusa R. Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos Int. 2004;15:243-7. (Pubitemid 38391541)
72. Horcajada-Molteni MN, Chanteranne B, Lebecque P, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res. 2001;16:958-65. (Pubitemid 32332307)
73. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone via the sympathetic nervous system. Cell. 2002;111:305-17. (Pubitemid 35345151)
74. Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol. 2010;191:7-13.
75. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197-207. (Pubitemid 30064908)
76. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol. 2009;5:365-72.
77. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010;11:11-22.